Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Kura Oncology Stock Is Sliding Today


Shares of Kura Oncology (NASDAQ: KURA), a clinical-stage biopharmaceutical company, are down sharply in response to a clinical hold for the company's experimental leukemia treatment. The stock was down 15.6% as of 11:20 a.m. ET on Wednesday.

The Food and Drug Administration placed a partial clinical hold on a phase 1 trial with KO-539 after the death of a patient. The adverse event was potentially associated with differentiation syndrome (DS).

Image source: Getty Images.

Continue reading


Source Fool.com

Like: 0
Share

Comments